- Home
- BILL vs GH Comparison
BILL vs GH Comparison
Compare BILL & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BILL
- GH
- Stock Information
- Founded
- BILL 2006
- GH 2011
- Country
- BILL United States
- GH United States
- Employees
- BILL N/A
- GH N/A
- Industry
- BILL EDP Services
- GH Medical Specialities
- Sector
- BILL Technology
- GH Health Care
- Exchange
- BILL Nasdaq
- GH Nasdaq
- Market Cap
- BILL 4.7B
- GH 4.9B
- IPO Year
- BILL 2019
- GH 2018
- Fundamental
- Price
- BILL $52.91
- GH $64.34
- Analyst Decision
- BILL Buy
- GH Strong Buy
- Analyst Count
- BILL 21
- GH 22
- Target Price
- BILL $61.05
- GH $64.91
- AVG Volume (30 Days)
- BILL 3.6M
- GH 2.4M
- Earning Date
- BILL 11-06-2025
- GH 11-05-2025
- Dividend Yield
- BILL N/A
- GH N/A
- EPS Growth
- BILL N/A
- GH N/A
- EPS
- BILL N/A
- GH N/A
- Revenue
- BILL $1,462,570,000.00
- GH $828,849,000.00
- Revenue This Year
- BILL $12.40
- GH $28.30
- Revenue Next Year
- BILL $13.69
- GH $22.98
- P/E Ratio
- BILL N/A
- GH N/A
- Revenue Growth
- BILL 13.36
- GH 28.74
- 52 Week Low
- BILL $36.55
- GH $20.14
- 52 Week High
- BILL $100.19
- GH $68.00
- Technical
- Relative Strength Index (RSI)
- BILL 56.88
- GH 58.81
- Support Level
- BILL $51.90
- GH $60.46
- Resistance Level
- BILL $55.56
- GH $65.18
- Average True Range (ATR)
- BILL 1.98
- GH 2.50
- MACD
- BILL -0.34
- GH 0.07
- Stochastic Oscillator
- BILL 48.77
- GH 76.63
About BILL BILL Holdings Inc.
BILL Holdings Inc is a provider of software-as-a-service, cloud-based payments and spend and expense management products, which allow users to automate accounts payable and accounts receivable transactions, enable businesses to easily connect with their suppliers or customers to do business, eliminate expense reports, manage cash flows and improve back office efficiency. Initial Public Offering and Follow-on Offering.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.